Citrix Systems, Inc. (NASDAQ:CTXS) shares were trading lower by -0.79 percent ($-0.69) at $87 a piece in Wednesday’s session. It had closed the previous session at $87.69. CTXS trades with a P/S ratio of 4.46. This is lower than the industry’s 5.6 but higher compared with the wider sector’s 2.71. A low price-to-sales ratio, typically less than 1.0, is considered a good value. Also, it has an estimated price-earnings (P/E) multiple of 18.15 and a trailing 12-month price-earnings (P/E) multiple of 26.99. Shares of CTXS have uptrended 13% in the past three months, while the S&P 500 has moved 6.85% in that time. Citrix Systems, Inc. (CTXS) has a market cap of $13.17 billion and over the last 12 months, Citrix Systems, Inc. (NASDAQ:CTXS) has gone stronger by 24.24%. During the last 52 weeks, the (NASDAQ:CTXS) price has been as high as $88.08 and as low as $67.23. Citrix Systems, Inc. earnings have risen with an annualized rate of 12.8% over the last 5 years. The average 1-year price target for Citrix Systems, Inc. (CTXS) — averaging the work of different analysts — reveals a mean PT of $85.56/share. That’s a potential -1.66 decrease relative to where Citrix Systems, Inc. (NASDAQ:CTXS) has been trading recently. The current price is seen ranging between $86.52 and $87.7. There are brokerage firms with lower targets than the average, including one setting a price target of $60. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $109. The collective rating of 2.6 for Citrix Systems, Inc. (NASDAQ:CTXS) also leans strongly towards the neutral end of the spectrum. Of the 21 analysts surveyed by Reuters that track CTXS 10 of them rate its stock a hold. The other 11, though not evenly; between analysts who think you should buy Citrix Systems, Inc. versus those who think you should sell it. A 9 analysts rate it as either a buy or a strong buy, while2 believe that investors should either steer clear of CTXS or, if they already own its stock, sell it. Abbott Laboratories (ABT) knifed -0.79 percent lower and now trades for $55.58. ABT comes in with a P/S ratio of 3.83 that’s greater than 1, potentially implying that it could be expensive relative to the overall sector (5.41) and its peers (3.9). Also, it has an estimated price-earnings (P/E) multiple of 19.67 and a trailing 12-month price-earnings (P/E) multiple of 45.82. During the last 52 weeks, the price has been as high as $56.69 and as low as $37.38. Abbott Laboratories (NYSE:ABT) earnings have declined with a quarterly rate of -0.5% over the last 5 years. Shares of ABT have increased 10.92% in the past three monthswhile the S&P 500 has gained 4.02% in that time. Abbott Laboratories (NYSE:ABT) has a market cap of $96.17 billion and over the last 12 months, ABT has risen by 43.51%. The average 1-year price target for (ABT) reveals an average price target of $60.67 per share. That’s a potential 9.16 gain from where (NYSE:ABT) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $47. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $68. The consensus recommendation — averaging the work of 19 analysts — of 2 for Abbott Laboratories (ABT) points to moderate case. Of the analysts surveyed by Reuters that track Abbott Laboratories 6 of them rate its stock a hold. The other 13 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 13 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:ABT) or, if they already own its stock, sell it.




(adsbygoogle = window.adsbygoogle || []).push({});
